Efficacy and safety of drugs for ulcerative colitis
- PMID: 20377475
- DOI: 10.1517/14740331003639412
Efficacy and safety of drugs for ulcerative colitis
Abstract
Importance of the field: Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon that carries considerable burden and morbidity for patients and presents a constant challenge in management for gastroenterologists. Continued advances in medical therapies provide a range of treatment options for patients, but with this is the need to balance the potential benefits of a particular medication with its side effect profile in both the short and the long term.
Areas covered in this review: This article will review the current drugs used in the treatment of UC, including 5-amninosalicylates, antibiotics, steroids, immunomodulators and biologics, with particular attention to their indications, efficacy and toxicity profile.
What the reader will gain: The reader will gain a comprehensive understanding of the various medical therapies used in the treatment of UC with focus on efficacy and toxicity profiles, allowing providers to choose appropriate medical therapies for their patients.
Take home message: The particular agent used depends upon the extent and severity of disease, with mild-to-moderate disease treated with conventional therapy including 5-amninosalicylates. Steroids are used in the short term to bring active disease into remission, and the more aggressive immunomodulators and biologics are reserved for more severe disease given their toxicity profiles.
Similar articles
-
A review of infliximab use in ulcerative colitis.Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Clin Ther. 2008. PMID: 18343261 Review.
-
Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.Clin Ther. 2010 Feb;32(2):238-45. doi: 10.1016/j.clinthera.2010.02.010. Clin Ther. 2010. PMID: 20206781
-
Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.Digestion. 2008;77 Suppl 1:36-41. doi: 10.1159/000111486. Epub 2008 Jan 18. Digestion. 2008. PMID: 18204260 Review.
-
Infliximab in ulcerative colitis.Gastroenterol Clin North Am. 2006 Dec;35(4):821-36. doi: 10.1016/j.gtc.2006.09.002. Gastroenterol Clin North Am. 2006. PMID: 17129815 Review.
-
Emerging drugs to treat Crohn's disease.Expert Opin Emerg Drugs. 2010 Jun;15(2):309-22. doi: 10.1517/14728214.2010.480972. Expert Opin Emerg Drugs. 2010. PMID: 20402560 Review.
Cited by
-
The potential mechanism of huazhuojiedu decoction in the treatment of ulcerative colitis based on network pharmacology and experimental validation.Front Pharmacol. 2022 Oct 14;13:1033874. doi: 10.3389/fphar.2022.1033874. eCollection 2022. Front Pharmacol. 2022. PMID: 36313293 Free PMC article.
-
An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis.Sci Rep. 2016 May 24;6:26585. doi: 10.1038/srep26585. Sci Rep. 2016. PMID: 27215610 Free PMC article.
-
Qingchi San treats ulcerative colitis in mice by inhibiting the nuclear factor-kappa B signaling pathway and Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 inflammasome formation.J Tradit Chin Med. 2023 Feb;43(1):68-77. doi: 10.19852/j.cnki.jtcm.20220928.001. J Tradit Chin Med. 2023. PMID: 36639997 Free PMC article.
-
BTZO-15, an ARE-activator, ameliorates DSS- and TNBS-induced colitis in rats.PLoS One. 2011;6(8):e23256. doi: 10.1371/journal.pone.0023256. Epub 2011 Aug 10. PLoS One. 2011. PMID: 21853095 Free PMC article.
-
Dandelion root extract protects NCM460 colonic cells and relieves experimental mouse colitis.J Nat Med. 2018 Sep;72(4):857-866. doi: 10.1007/s11418-018-1217-7. Epub 2018 May 8. J Nat Med. 2018. PMID: 29740735
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials